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SummAry Psoriasis vulgaris (PV) is a systemic inflammatory disease 
in which immune and genetic factors are involved in the pathogenesis. 
Some treatment approaches in PV patients have been similar to thera-
py of some tumors. This fact has led to a new scientific approach to PV 
not only as an inflammatory disease, but also as a benign epidermal 
hyperplasia or a benign tumor. In this article, we hypothesize that there 
has been a parallel between some benign tumors and neoplasms and 
PV. The aim of this article is to present the approach to PV as an inflam-
matory disease as well as benign epidermal hyperplasia or tumor, and 
to introduce a new meaning.
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IntroDuCtIon
Psoriasis vulgaris (PV) is an inflammatory skin dis-
ease that affects skin and joints. In its most severe, 
erythrodermic variant, it affects the whole skin. Re-
cently, the role of many tumor growth factors in the 
pathogenesis of PV has been identified. Prominent 
epidermal hyperplasia has been one of the derma-
tohistopathologic signs of PV. This could explain 
the fact why psoriasis affects some parts of the skin, 
while the other parts are spared. This clinical picture 
is similar to benign tumors like fibropapillomas and 
seborrheic keratoses or verrucae vulgaris, as found 
in verrucous PV (1). Considering this fact, PV could 
be included in differential diagnosis of some benign 
epidermal tumors. Therapy for PV includes cytostatics 
and immunosuppressants, suggesting that PV could 
be a variant of an epidermal tumor. In flaring clinical 
picture of PV, histopathology shows dense perivascu-
lar infiltrate in the upper part of the dermis, edema 
of papillary dermis, dilated capillaries, psoriasiform 
hyperplasia with equal epidermal tracks, with little 
or no spongiosis in the lower parts of the dermis, 
spongiform pustule of Kogoj, no stratum granulo-
sum and confluent parakeratosis with collection of 
neutrophils in stratum corneum (2). Acanthotic epi-
dermis is thickened four to five times in contrast to 
normal epidermis. Furthermore, by light microscopy 
one can see acanthosis in spinous layer and enlarged 
epidermal papillae with mitoses in basal and supra-
basal layers. These data suggest hyperproliferation 
of keratinocytes and disorder of their differentiation. 
The control of keratinocyte growth is performed by 
different growth factors like epidermal growth factor 
(EGF) and transforming growth factor α2 (TGFα2) (3). 
By investigating the culture of keratinocytes and PV 
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patients in vivo, it has been demonstrated that more 
mitoses were present in the epidermis of psoriatic pa-
tients than in healthy population.
DISCuSSIon
Research on proliferating cell nuclear antigen 
(PCNA) and administration of monoclonal antibody 
Ki-67 to psoriatic patients has demonstrated that the 
epidermis in psoriatic patients was characterized by 
hyperproliferation of keratinocytes (4). Other inves-
tigations demonstrated that in vitro psoriatic dermal 
fibroblasts could initiate hyperproliferation of kerati-
nocytes. Similar role could belong to Langerhans and 
other dendritic cells, which can release tumor ne-
crosis factor α (TNF-α) and interleukin-12 (IL-12) (5). 
The expression of vascular endothelial growth factor 
(VEGF), which is coded by genes on 6th chromosome, 
is increased in psoriatic lesion. According to the ex-
periments, keratinocytes and fibroblasts secrete VEGF. 
Recent researches confirm that psoriatic plaque dem-
onstrates a differentiated lymphoid organ. These the-
ses could be important in the tendency of stopping 
the development of lymphoid tissue in psoriatic skin 
for future treatments of PV. Admission of vascular re-
serves into the skin is provided by chemotactic pro-
tein derivatives, including IL-8 and growth-regulated 
oncogene-α (GRO-α) (6). Serum levels of interferon-
gamma (INF-γ) correlate with the intensity of the 
disease, and it was observed that therapy with cyclo-
sporine A or etretinate rapidly decreased serum lev-
els of IFN-γ (7). Depending on the stimulation, it has 
been demonstrated that the connection leukocyte 
function-associated antigen-1/intracellular adhesion 
molecule-1 (LFA-1/ICAM-1) played an important role 
in T-cell proliferation (8). Keratinocytes treated with 
IFN-γ are capable of interposing bacterial superanti-
gen induced T-cell proliferation by superficial ICAM-
1. Immunostimulative function of keratinocytes is 
primarily provided through ICAM-1 and LFA-1 signal 
on T-cells (8). In PV, there is expression of angiogenic 
factors like VEGF and basic fibroblast growth factor 
(BFGF), which raise the levels of angiopoietin 2 and 
tyrosine kinase-2 (Tie2) expression on endothelial 
cells (9). There are many data proved by the authors 
that adhesion molecules such as ICAM-1, vascular cell 
adhesion molecule-1 (VCAM-1) and E selectin play an 
important role in pathogenesis of PV. But, there are 
many papers which prove that the same molecules 
also play important roles in the pathogenesis of tu-
mors. Kobayashi et al. also confirmed that cell ad-
hesion molecules (CAMs) such as ICAM-1, VCAM-1, 
E-selectin and P selectin are important in the patho-
genesis of inflammation (10). This fact may explain 
the connection between inflammation and tumori-
genesis (10). Indirectly, it has already been proven by 
the benefit of anti-inflammatory drugs used in cancer 
treatment (10). Natural killer/T lymphocyte (NK/T) 
cells play their role in the development of psoriatic 
plaques. NK/T cells and their receptors are important 
in the late phase of psoriatic process (11). INF-γ and 
TNF-α stimulate the expression of ICAM-1 in in vitro 
keratinocytes (12). These authors have demonstrated 
stronger expression in hyperproliferative keratino-
cytes induced by IL-1α (12). There were many stud-
ies indirectly supporting this hypothesis. Brody et 
al. showed that epidermal hyperplasia was present 
in 2-day psoriatic plaque (13). PUVA bath therapy ex 
juvantibus reduces epidermal hyperplasia in 90% of 
treated patients. Epidermal acanthosis was reduced 
in 40% of patients after 2-week therapy and in 66% 
of patients by the end of PUVA treatment (14). Other 
authors found decreasing expression of the adhesion 
molecules ICAM-1 and VCAM-1 in psoriatic patients 
after PUVA and UVB therapy (15). The importance of 
the adhesion molecules proved the hypothesis and 
papers reporting increased expression of the ICAM-1 
and VCAM-1 in lesional and non-lesional skin of pso-
riatic patients (16). Murphy et al. demonstrated that 
epidermal hyperplasia was the most prominent histo-
pathologic disorder in the early and resolving psoria-
siform lesion (17). Dermatoscopy allows diagnosing 
of malignant tumors, especially pigmented, although 
it has its advantages in diagnosing inflammatory 
diseases. Blum et al. demonstrated dermatoscopic 
picture of PV as symmetrically homogeneous and 
bunch-like arranged. Pinpoint-like capillaries had the 
same appearance in PV and in clear-cell acanthoma, 
a tumor characterized as benign epidermal hyperpla-
sia (18). Papules and plaques, which resemble verruca 
vulgaris, a benign epidermal hyperplasia caused by 
HPV viruses, could be seen in the clinical picture of 
PV. Khalil et al. have supported this hypothesis and 
demonstrated prominent epidermal hyperplasia in 
the histopathologic picture of papules and plaques in 
psoriatic patients (1). Some authors showed that pro-
liferation of the bcl-2, Ki-67 and TUNEL markers was 
significantly higher in psoriatic epidermis as com-
pared with the healthy one (19). Zippin et al. exam-
ined soluble adenylyl cyclase (sAC) in hyperprolifera-
tive disorders of the skin like PV, verruca vulgaris and 
squamous cell carcinoma in situ on sun damaged skin 
and demonstrated that keratinocytes were stained 
predominantly nuclear (20). The authors conclude 
that sAC could play a role in the pathogenesis of hy-
perproliferative disorders like PV (20). Putative human 
homologue of yeast CDC47 is member of the mini-
chromosome maintenance protein family (hCDC47) 
and is a component of the regulatory mechanism 
in cell proliferation. Hiraiwa et al. compared the pat-
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terns of distribution of putative human homologue 
of yeast CDC47 and (hCDC47) positive cells in tumors 
and PV (21). In keratoacathomas and PV, distribution 
was similar as peripheral type of location positive 
cells, which also supports our hypothesis that PV may 
also be a benign epidermal hyperplasia (21).
ConCLuSIon
We suggest that PV and some tumors have in part 
equal pathogenesis and that PV could be both a vari-
ant of hyperproliferative benign tumor as well as an in-
flammatory disease. We can conclude that PV, although 
characterized as a systemic inflammatory disease, has 
elements of benign epidermal hyperplasia and further 
researches are needed to elucidate this hypothesis.
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